Please login to the form below

Envision Pharma Group expands capabilities with specialist behavioral science offering Envision the Change

HORSHAM, UK, APRIL 5, 2022 – Leading global technology-enabled scientific communications company Envision Pharma Group has launched a suite of behavioral science-led solutions to expand the group’s capabilities and optimize value offering to its clients.

Envision the Change is spearheaded by Mark Lakeram (Global Lead, Behavioral Science) and supported by Directors Jenny Squibbs (in the UK) and Justine Swann (in the US). As a dedicated team of behavioral scientists, they understand that to affect real change the intricacies and realities of everyday life and health need to be considered.

Lakeram said, “All healthcare decisions are influenced by human behavior. By taking into account the science behind this, our proprietary Feel-Think-DoTM model helps to decode why people make the decisions they do. From strategic and tactical planning, to aiding information recall through data visualization and adult learning techniques – we provide counsel and support to drive behavior change that ultimately improves health outcomes.”

Susanne Clark, Head of Envision Scientific Solutions, added, “No matter what product challenges are ahead, understanding the behavior of key stakeholders will be paramount. I’m delighted that we’ve strengthened our service offering with Envision the Change in order to support our clients across all aspects of medical affairs and marketing, from planning to creative implementation for both external and internal audiences.”


About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies. Learn more at:

For further information:

Marsha Caplin
Global Head of Marketing
Envision Pharma Group
Tel: +44 (0)7557 083549

5th April 2022


Company Details

Envision Pharma Group

01403 322 000

Contact Website

Envision House
5 North Street
West Sussex
RH12 1XQ

Latest content on this profile

Envision Pharma Group and Alucio™ partner to power next-generation scientific exchange for the life science industry
Collaboration capitalizes on Alucio’s flagship Beacon platform and Envision’s global leadership in medical strategy and healthcare communications
Envision Pharma Group
Envision Pharma Group appoints Head of Envision Value & Access
Envision Pharma Group is pleased to announce the appointment of Mel Formica as its Head of Envision Value & Access.
Envision Pharma Group
Envision Pharma Group appoints new CEO
Meg Heim named as its new Chief Executive Officer
Envision Pharma Group
Envision Pharma Group partners with scite to display Smart Citations in iEnvision® – the global medical affairs platform
Smart Citations will feature in Library, Datavision®, and Scientific Communication Platform modules
Envision Pharma Group
Envision Pharma Group expands capabilities with specialist behavioral science offering Envision the Change

Envision Pharma Group
Envision Pharma Group and Vitaccess create a global partnership to power evidence generation for the biopharmaceutical industry
Move combines Envision’s global leadership position in medical affairs communications with Vitaccess’ award-winning capabilities in real-world evidence (RWE)
Envision Pharma Group